The present meta-analysis was carried out to determine whether supplementation with glutamine (Gln) would reduce the intestinal inflammatory response and mucosal permeability in patients undergoing abdominal surgery. The PubMed, EMBASE, Web of Science, and The Cochrane Library databases
were searched for randomized controlled trials on the effects of supplementation with Gln, and published from August, 1966 to June 2014. Inclusion criteria for the meta-analysis were: i) Study design was a randomized controlled trial, ii) study included patients undergoing
abdominal surgery, iii) study patients received a supplementation with Gln peptide (AlaGln or GlyGln) whereas control patients did not use any supplements, and iv) study outcomes included inflammatory markers [Creactive protein (CRP), tumor necrosis factorα (TNFα), and
interleukin (IL)6, and IL2 receptor] and markers of intestinal permeability [lactulose/mannitol, diamine oxidase, D()lactic acid, and endotoxin]. Qualities of controlled trials were assessed using the Jadad score. Metaanalyses were performed with fixed or randomeffect models depending
on the heterogeneity of studies. There were 21 trials meeting the inclusion criteria. The metaanalysis revealed that the levels of CRP, TNFα, and IL6 in patients supplemented with Gln were significantly lower than those in control patients, whereas the levels of IL2 receptor were
increased by Gln supplementation. Gln also significantly decreased the lactulose/mannitol ratio, the levels of diamine oxidase and endotoxin, and tended to decrease the levels of cyclic Dlactic acid. In conclusion, Gln appears to effectively reduce the inflammatory response and intestinal
mucosal permeability in patients after abdominal surgery.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Nutrition, Jinshan Hospital, Fudan University School of Medicine, Shanghai 201508, P.R. China
Tongji University School of Medicine, Shanghai 200092, P.R. China
Publication date: January 1, 2016
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites